|
|
|
|
|
|
|
23.02.26 - 08:18
|
Wave of Chinese biotech deals builds as Harbour BioMed, Solstice sign US$1.2 billion pact (SCMP)
|
|
|
China's Harbour BioMed has struck a deal worth more than US$1.2 billion with a clinical-stage biotechnology company to develop and commercialise an antibody outside China, as the country's novel drug makers increasingly secure not only upfront licensing fees but also long-term international partnerships.
The Shanghai-based company announced a licence and equity agreement on Monday with Solstice Oncology, a firm established by a syndicate of venture capital investors, for the exclusive......
|
|
|
|
|
|
|
21.01.26 - 00:36
|
Harbour BioMed stake in US drug firm Spruce shows Chinese firms′ growing clout, analysts say (SCMP)
|
|
|
Shanghai-based Harbour BioMed's acquisition of a stake in US-based Spruce Biosciences is the latest example of China's novel drug developers progressing from one-time licensing deals into long-lasting equity partnerships with overseas partners.
The deal, detailed in a Hong Kong stock exchange filing on Monday, also showed Chinese firms' growing clout on the global pharmaceutical stage, analysts said.
“The coming years will see more Chinese biotech firms engaging in equity investments and joint......
|
|
|
|
|
12.01.26 - 14:42
|
Control Devices Acquires Sherwood Valve (PR Newswire)
|
|
|
Expansion of flow control solutions across industrial gas, specialty gas, high-purity gas, and medical gas applications. ST. LOUIS, Jan. 12, 2026 /PRNewswire/ -- Control Devices, a portfolio company of HBM Holdings, today announced the acquisition of Sherwood Valve. The acquisition......
|
|
|
|
|
17.12.25 - 12:24
|
Harbour BioMed and BMS sign multi-specific antibody collab (PBR)
|
|
|
Harbour BioMed will work alongside BMS to progress and expedite the programmes aimed at the discovery of the antibodies. Harbour BioMed, in exchange, is eligible to obtain payments
The post Harbour BioMed and BMS sign multi-specific antibody collab appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27.08.25 - 16:42
|
Harbour BioMed Reports 2025 Interim Results (PR Newswire)
|
|
|
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today......
|
|
|
25.08.25 - 03:03
|
Harbour BioMed Appoints Yajie Li as Chief Medical Officer (PR Newswire)
|
|
|
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 24, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
